|
scrc announced strategic partnership with chempartner
shanghai clinical research center (scrc) and shanghai chempartner co. ltd. (chempartner), a wholly owned subsidiary of shangpharma corporation, announced today a strategic partnership to provide fully integrated r&d services covering discovery, pre-clinical and clinical development.
rongxing gan, ceo of scrc, commented, "we are very glad to work with chempartner. i firmly believe the partnership with chempartner will not only benefit the development of both companies, but also contribute to the development of innovation strategy for bio-pharmaceutical industry in china. we look forward to building a long term and fruitful cooperation relationship in between our two companies in the future."
"we are pleased to enter into a strategic partnership with shanghai clinical research center, a pioneering full-service clinical research platform with strong government support and international standards," said michael hui, chairman and ceo of chempartner, "i am confident that this collaboration will compliment chempartner´s existing integrated drug r&d service capabilities by offering more value-added services to global and domestic pharmaceutical and biotech companies."
about shanghai chempartner
founded in 2003, shanghai chempartner company ltd. (chempartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, dmpk, toxicology, process r&d, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. chempartner currently has a team of over 1000 dedicated scientists including more than 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.
further information is available at http://www.shangpharma.com.
|
